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BIOTECHNOLOGY AT THE CROSSROADS 
IS REGULATION THE GATEKEEPER?
As of May 1991, the United States Department of Agriculture (USDA) had 
approved approximately 120 applications for small-scale field trials of
transgenic plants and several genetically engi-
neered animal biologies had been approved for 
marketing. The Food and Drug Administration 
(FDA) had approved for commercial use one 
biotechnologically derived food enzyme and the 
Environmental Protection Agency (EPA) had al-
lowed a handful of genetically engineered pesti-
cides and other organisms to be used in the field 
and in closed systems. As the science of molecu-
lar biology appear to progress, quickly bringing 
agricultural applications of biotechnology 
closer to the marketplace, we, the organizers of 
this third NABC meeting, thought the time ap-
propriate to focus our discussions on biological, social and institutional 
questions voiced about biotechnology and how concerns might affect the 
pace of development and commercialization of agricultural biotechnology.
My task today is to review the regulatory structure for the agricultural 
products of biotechnology. After a brief introduction, where I adopt the 
viewpoint that agricultural biotechnology is at “a crossroad,” I will present, 
in an historical context, an overview of the current regulatory system and 
conclude with an evaluation of the effect of the regulatory framework on 
the pace of commercialization. My conclusion is that consumer acceptance 
and scientific problems, as well as problems in the regulatory system, will 
continue to slow the pace of approval of the products of agricultural 
biotechnology.
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IS AGRICULTURAL BIOTECHNOLOGY AT A CROSSROADS?
There is little doubt that agriculture has been, and regardless of the pace 
of regulatory approvals, will continue to be greatly affected by biotechnol-
ogy. New crops are being developed, as are new animal drugs and vac-
cines, and there is an explosion of understanding about the basic biology 
in agricultural systems. Today there are several new agricultural biotech-
nology companies and most of the large traditional players in the agricul-
tural sector—seed companies, pesticide companies, livestock producers 
and food processors—have biotechnology initiatives. Therefore, from a 
long-term perspective, agriculture and biotechnology appear as healthy 
partners.
From a short-term commercial perspective, however, agricultural ap-
plications of biotechnology appear to be at a crossroads. There are many 
strong supporters for the majority of agricultural applications of biotech-
nology in agriculture. However, unlike their biomedical cousins, which 
have been viewed from the outset as valuable and have been commercial-
ized almost without controversy, questions have been raised by some from 
the very beginning about the need for, and the social, political, economic 
and safety implications of initial targets for commercialization of biotech-
nology in agriculture. Wide-ranging public debate has taken place long 
before any products have entered the commercial arena. Focusing not just 
on the traditional concerns of environmental and human safety, but on 
new criteria such as potential economic, social and philosophical issues, 
the debate has made the process of formulating a rational regulatory 
scheme more uncertain and protracted. Coupled with a shortage of 
agency resources, the pace of agency consideration and development of 
policies toward products of biotechnology used in agriculture has been 
slow and the resulting uncertainty and cost has caused a number of the 
smaller companies to depart from the industry as well as a reduction in 
the efforts of some larger companies.
Therefore there is a “crossroad”—the smaller companies may not have 
the wherewithal to last through the continuing debate and regulatory un-
certainty. In my view, the question is not whether biotechnology will be 
commercialized in agriculture, but when and by whom. Of the four deter-
minants—science, intellectual property, regulations and acceptance by
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consumers, farmers and processors—I will be focusing on the latter two. 
The question I ask at this point is, “Have we created a system in which only 
the biggest or largest can survive?”
OVERVIEW OF THE REGULATORY FRAMEWORK
In June 1986, the President’s Office of Science Technology Policy (OSTP) Have we 
published the Coordinated Framework for the Regulation of Biotechnol- created a 
ogy (51 Federal Register, 23302 et seq., June 26,1986). In 1987, USDA pub- system in 
lished a revision to the 1986 proposal, (52 Federal Register 22892, June 16, which only the
1987). These documents contain the basic framework for the regulatory biggest or
oversight of the products of biotechnology. The development of the largest can
framework can be traced back to the 1970s. survive?
HISTORICAL LESSONS
The history of recombinant DNA regulation, a period of only 15 years, is 
instructive for the current debate. The history can be viewed in three 
parts. The first period, ending in about 1978, was characterized by conjec-
tural fears about laboratory-based research, raised initially by the scien-
tific practitioners and then spread into the political and public arena. Not-
withstanding numerous Congressional hearings and media attention, the 
issues were largely laid to rest as a result of the adoption of “guidelines” is-
sued by the National Institutes of Health (NIH). The NIH Guidelines set 
the standard and today, as laboratory experience has allowed relaxation of 
the Guidelines, 90 percent of laboratory research is exempt from the 
Guidelines.
Some observations about this period are instructive when contrasted to 
the current debate. One, a scientific and political consensus was devel-
oped within a relatively short period of time, approximately three years. 
The NIH played a major role, together with the scientific community, in 
helping to allay public fears and put in place flexible, yet credible, guide-
lines. Two, the regulations were entirely process-based; that is, the regula-
tions focused entirely on recombinant DNA molecules; there was no ef-
forts to recast all regulatory authorities to the new science. Three, the 
Guidelines focus on lab experimentation, primarily in the biomedical 
field; environmental releases were generally prohibited.
Is Regulation the Gatekeeper?
The second period of the regulation, or oversight of recombinant DNA 
technology, begins in the early 1980s and was highlighted by the commer-
cialization of the initial biomedical applications of the technology and the 
development of potential agricultural and environmental applications of 
biotechnology. The biomedical field turned out to be largely non-contro- 
versial; agricultural applications sparked a significant debate which is on-
going.
Two observations seem appropriate. First, because the initial biomedi-
cal products were viewed as potentially lifesaving or dealing with serious 
diseases, none raised significant public policy questions. Second, the 
products were the providence of one agency—FDA—and traditional con-
cerns were focused on in the FDA regulatory structure, e.g., safety and ef-
ficacy1.
In contrast, agricultural and environmental biotechnology products 
were viewed as presenting a very different perspective because living or-
ganisms were to be introduced into the environment or intended for hu-
man consumption. Started by a series of congressional hearings before the 
Oversight Subcommittee of the House Science and Technology Commit-
tee, and continued with a review by the White House, the new applica-
tions of biotechnology were examined to determine whether the current 
laws and regulations were adequate to protect the public while not unduly 
impeding the technology. It is this debate that is still going on, now almost 
a decade later.
As before, several observations seem useful. First, the focus of the de-
bate shifted from laboratory experiments by academic researchers and de-
velopment of lifesaving medicines, to planned introduction by companies 
into the environment of genetically modified plants, animals and mi-
crobes and to introduction into the food chain of food products from 
these organisms. Second, because of the wide ranging potential uses of 
these new products several agencies were now involved, frequently in ar-
eas where they either had not previously regulated or in overlapping areas. 
In addition to FDA, agricultural applications involve principally EPA and 
USDA. As a result, there have been and continue to be, disagreements
'While FDA has had to address many issues involved in evaluating new 
biotechnology products, the issues have been mostly traditional concerns in the 
drug approval process.
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about the scope of the organisms reviewed, agency jurisdiction and risks 
and benefits of specific applications.
The third period of regulatory oversight of biotechnology begins with 
the publication of the Framework in 1986 and continues into the present. 
During this period the agencies reviewed various applications involving 
mostly small scale field trials. While unsuccessful, there were also many 
EPA efforts to modify the Framework in light of increasing experience and 
efforts by USDA to develop guidance for large scale testing and commer-
cialization of biotechnology products.
The Framework addresses the jurisdictional basis of the regulation of 
the products of biotechnology; it describes EPA’s, USDA’s and FDA’s juris-
diction, together with that of NIH and the Occupational Safety and 
Health Administration. The Framework is grounded in four principles. 
The first is that existing statues are sufficient; e.g., no new laws are neces-
sary. The second principle is that the product, and not the process used to 
develop the product, would be the regulatory focus—the basis of regula-
tion would be the end product and not how that product was produced. 
The third is that regulation would proceed on a case-by-case basis, and 
not by class, until there was sufficient information to make determina-
tions about the safety or lack of safety of classes of products. The fourth 
principle is that the agencies would attempt to coordinate and to work re-
views in conjunction with one another, rather than sequentially.
The Framework principally focuses on small-scale introductions and, 
while describing in some detail agency programs for approval of tradi-
tional products, it provides little guidance on large scale and commercial 
issues. Several applications, for example, transgenic animals, are not dis-
cussed, nor are regulatory questions with respect to commercialization of 
products of transgenic plants, the registration of pesticides or herbicide- 
tolerant crops Notwithstanding its deficiencies, the agencies and particu-
larly USDA, have used the Framework as a mechanism to allow some re-
search applications to move into the field trial stage.
A brief description of each agency’s regulatory program follows.
USDA—The Animal, Plant Health and Inspection Service (APHIS), rely-
ing on the Federal Plant Pest Act (7 U.S.C. §§ 150aa-150jj) requires that a 
permit application be filed before movement, defined to include an envi-
ronmental introduction, of any organism produced via genetic engineering
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which has a plant pest source (donor, vector or recipient) and any organ-
ism having a potential plant pest risk. Principal concerns of APHIS have 
been the source of the organism and its ability to present a risk to agricul-
ture. The agency has also used its authority under the National Environ-
mental Policy Act (42 U.S.C. §§ 4321-4370) to conduct environmental 
assessments.
To date, APHIS has granted approximately 1,000 permits for movement 
of genetically engineered organisms for lab research and approximately 
120 permits for actual field trials. Of the field trial permits, about 40 per-
cent have involved herbicide tolerant plants, with the balance for pest and 
viral resistance and some few for plants with compositional modifica-
tions. In addition to tobacco and tomatoes, the initial targets, many veg-
etable and some tree and fruit crops, have been tested in the field.
Under the authority of the Virus, Serum and Toxin Act (21 U.S.C. §§ 
151-158) APHIS regulates production and sale of animal biologies, such as 
animal vaccines and some diagnostic tests used in the treatment, preven-
tion, cure and diagnosis of diseases of animals. APHIS has approved three 
licenses for a recombinant vaccine and approved field testing of another 
vaccine. The basic questions asked by APHIS in the review are traditional 
to agency concerns: potency, purity, efficacy and safety. APHIS also evalu-
ates environmental considerations and on one such occasion, environ-
mental issues have held up a permit approval.
Most observers believe that APHIS’s program for review and permitting 
small scale trials of plants has been successful; APHIS has allowed for pub-
lic and state participation and has conducted credible reviews on a timely 
basis. APHIS also has sought to stimulate thinking about downstream 
considerations by sponsorship of conferences, such as the meeting on 
transgenic maize held at the Keystone Center.
EPA—EPA’s biotechnology policy relies on its authority under the Federal 
Insecticide, Fungicide and Rodenticide Act (FIFRA) (7 U.S.C. §§ 136- 
i36y) and the Toxic Substances Control Act (TSCA) (15 U.S.C. §§ 2601- 
2629), to regulate pesticides and chemicals respectively.
Chemicals, which EPA has defined to include DNA, are subject to a 
90-day premanufacture notification requirement, if they are not on EPA’s 
inventory of existing chemicals in commerce. EPA’s review has focused on 
enhancement of the host range of the modified organism and the ability of
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the organism to affect the ecosystem and human health. EPA has received 
notification for small-scale field testing of microbes used for nitrogen 
fixation and for several genetically modified microorganisms used in 
closed systems to produce enzymes for non-FDA regulated uses. (The en-
zyme itself is treated as traditional chemicals for regulatory purposes.) 
Taxonomy has been a major issue for EPA as well as definitions for the 
scope of organisms subject to review.
Under its FIFRA policy EPA focuses on the small scale field testing of 
biological pest control agents. EPA adopted a policy of requiring agency 
notification prior to any field testing of certain genetically modified or-
ganisms. EPA has received several notifications, and most small-scale tri-
als have proceeded without the need for an experimental use permit. 
(Field tests of chemical pesticides on less than ten acres remain exempt 
from notification and experimental use permit requirements.)
EPA has not been successful in modifying its 1986 policy statement not-
withstanding several efforts that have come to the proposal stage. Dis-
agreements about the scope of organisms subject to notification and regu-
lation, as well as agency turf battling, have led to this stalemate, but many 
are hopeful that the current proposed revisions will be published and the 
public debate will begin. Not addressed in the revisions, and still to be de-
cided are the downstream issues: how to regulate, if at all, plants with in-
creased pesticidal properties, whether to regulate herbicide tolerant crops, 
and how to address the tolerance/residue issues.
FDA—FDA regulates in several areas which affect the agricultural appli-
cations of biotechnology including food and animal feed, food additives, 
animal drugs and possibly transgenic animals. FDA’s basic authority is the 
Federal Food Drug and Cosmetic Act (FFDC Act) (21 U.S.C. §§ 301-392). 
While FDA has approved several genetically engineered foods, animal bio-
logical for human use, no genetically engineered foods, animal drugs or 
feed additives have been approved as yet. One food enzyme has been ap-
proved.
FDA has not generally provided guidance as to how it will regulate the 
products of biotechnology, though it has stated on more than one occa-
sion that it will rely on its traditional programs. FDA does not regulate 
foods on a pre-market clearance basis. Traditionally bred crops have been mar-
keted without FDA clearance, subject only to the general responsibility of
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the food company to assure the safety of the food, e.g., conformance with 
the adulteration provision of the FFDC Act. Food additives or substances 
which are added to foods or become constituents of foods, must be “gen-
erally recognized as safe” (GRAS), or the subject of an approved food/feed 
additive regulation.
Animal drugs are also regulated by FDA in much the same manner as 
human drugs. In addition to proving target animal safety and efficacy a 
sponsor must also demonstrate that the drug does not produce harmful 
residues in edible food. An additional difficulty for those involved in the 
animal health field is that there is a split of jurisdiction between FDA and 
USDA, with FDA regulating animal drugs and some diagnostics and 
USDA regulating animal biologies and some other diagnostics. How ones’ 
product is categorized has significant ramifications, with respect to which 
agency regulates, as well as to how the product is regulated.
THE REGULATORY ROADBLOCK?
While the Framework has permitted significant progress since its adop-
tion in 1986, major uncertainties exist with regard to the future. These un-
certainties will need to be resolved before one working in the field can 
have any reasonable degree of assurance that a safe product will be allowed 
to reach the marketplace on a timely basis and become a success or failure, 
depending on its value to the consumer. In my view, three things must 
happen so that the regulatory process does not become a roadblock.
The first is establishment of clear jurisdictional lines. While many of the 
questions as to “who” regulates the “what” have been decided with respect 
to field testing, significant questions remain unanswered regarding large 
scale testing and commercial approval. For example, it is unclear who will 
regulate commercialization of transgenic crops with enhanced pesticidal 
properties and how food and feed tolerances will be set. No clear policy 
has been articulated for transgenic animals. Questions also remain about 
the scope of the organisms subject to initial or commercial oversight.
A regulatory roadmap would give the regulated industry, the scientific 
community, public interest groups and consumers answers to questions— 
who has jurisdiction, how that jurisdiction will be exercised, and what is 
expected in order to obtain regulatory decisions.
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Second is credibility. The agency charged with the responsibility must 
be able to render a credible decision. As an initial matter, the agency must 
have the necessary expertise. The regulatory process also must allow for 
appropriate public participation of decisions and communication of re-
sults.
A significant question yet to be answered is whether the regulatory pro-
cess will focus on safety and efficacy, or whether the regulatory process 
will become the place for protracted debates about potential social and 
economic implications of the technology. This question is an essential one 
for the agricultural sector where the primary debate about products like 
bovine somatotropin have very little to do with safety and more to do with 
potential questions about the changing structure of agriculture.
Third is timeliness; can the agency make the decision on a timely basis? 
As an initial matter, the agency must have sufficient resources. The 
agency’s process must also provide reasonable time frames for decisions. A 
decision that takes an unnecessary amount of time, particularly in an area 
where the technology is moving rapidly, benefits no one.
CONCLUSION
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As I have discussed, I do not believe that regulatory processes will be a 
roadblock to agricultural biotechnology in the long term. However, in the 
short term, the pace of approval of the products of agricultural biotech-
nology will be slowed by uncertainty.
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